Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
Key Highlights
- ➤Femasys will exhibit FemaSeed and FemVue at ASRM 2026, October 24–28
- ➤Femasys is expanding fertility offerings into OB/GYN practices and maintaining REI relationships
- ➤FemBloc is advancing toward U.S. FDA approval through the ongoing FINALE pivotal trial
- ➤FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025
Expert Statements
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“Our expansion into OB/GYN practices brings new options for earlier fertility evaluation and treatment into the care pathway, building on the established referral relationships between OB/GYNs and REIs.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“Our commitment to REIs and the patients referred to their fertility centers remains central to our commercialization strategy.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“FemaSeed offers REIs an additional treatment option for appropriately selected patients as they determine the next step in care, including when to proceed to IVF.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“We look forward to returning to ASRM to discuss how our portfolio can complement existing fertility services and expand options for patients across this connected care ecosystem.”
ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2026 Scientific Congress & Expo, taking place October 24–28 at the Baltimore Convention Center in Baltimore, Maryland. The Company will highlight FemaSeed(®) Intratubal Insemination (ITI), a first-step fertility treatment option, together with FemVue(®), its complementary diagnostic solution for in-office fallopian tube evaluation at booth #513.
“Our expansion into OB/GYN practices brings new options for earlier fertility evaluation and treatment into the care pathway, building on the established referral relationships between OB/GYNs and REIs,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. “Our commitment to REIs and the patients referred to their fertility centers remains central to our commercialization strategy. FemaSeed offers REIs an additional treatment option for appropriately selected patients as they determine the next step in care, including when to proceed to IVF. We look forward to returning to ASRM to discuss how our portfolio can complement existing fertility services and expand options for patients across this connected care ecosystem.”
Get started
Create a free account to read the full story.